Cannara Biotech Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Zohar Krivorot
Chief executive officer
CA$525.0k
Total compensation
| CEO salary percentage | 61.90% |
| CEO tenure | 7yrs |
| CEO ownership | n/a |
| Management average tenure | 3.2yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2025 | CA$525k | CA$325k | CA$13m |
| May 31 2025 | n/a | n/a | CA$16m |
| Feb 28 2025 | n/a | n/a | CA$13m |
| Nov 30 2024 | n/a | n/a | CA$7m |
| Aug 31 2024 | CA$300k | CA$300k | CA$6m |
| May 31 2024 | n/a | n/a | CA$5m |
| Feb 29 2024 | n/a | n/a | CA$6m |
| Nov 30 2023 | n/a | n/a | CA$9m |
| Aug 31 2023 | CA$300k | CA$300k | CA$7m |
| May 31 2023 | n/a | n/a | CA$5m |
| Feb 28 2023 | n/a | n/a | CA$3m |
| Nov 30 2022 | n/a | n/a | CA$3m |
| Aug 31 2022 | CA$75k | CA$75k | CA$2m |
| May 31 2022 | n/a | n/a | CA$884k |
| Feb 28 2022 | n/a | n/a | CA$1m |
| Nov 30 2021 | n/a | n/a | CA$1m |
| Aug 31 2021 | n/a | n/a | -CA$2m |
| May 31 2021 | n/a | n/a | -CA$7m |
| Feb 28 2021 | n/a | n/a | -CA$11m |
| Nov 30 2020 | n/a | n/a | -CA$13m |
| Aug 31 2020 | CA$92k | CA$92k | -CA$12m |
| May 31 2020 | n/a | n/a | -CA$12m |
| Feb 29 2020 | n/a | n/a | -CA$12m |
| Nov 30 2019 | n/a | n/a | -CA$13m |
| Aug 31 2019 | CA$150k | CA$150k | -CA$12m |
Compensation vs Market: Zohar's total compensation ($USD378.12K) is below average for companies of similar size in the US market ($USD572.27K).
Compensation vs Earnings: Zohar's compensation has increased by more than 20% in the past year.
CEO
Zohar Krivorot (48 yo)
Mr. Zohar Krivorot serves as Chief Executive Officer of Cannara Biotech Inc. since 2019, Director since December 31, 2018 and is its Founder, Chairman of the Board. He served as President at Cannara Biotec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7yrs | CA$525.00k | no data | |
| Chief Financial Officer | 5.2yrs | CA$525.00k | 0.64% $ 803.2k | |
| Chief Technology Officer | no data | CA$425.00k | no data | |
| General Counsel & VP Legal Affairs | no data | no data | 0.17% $ 217.7k | |
| Vice President of Commercial Strategy & Marketing | 2yrs | no data | no data | |
| Vice President of Sales | 2yrs | no data | no data | |
| Vice President of Human Resources | 3.2yrs | no data | no data | |
| Executive Officer | no data | CA$300.00k | no data |
Experienced Management: LOVF.F's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7.1yrs | CA$525.00k | no data | |
| Independent Lead Director | 5.2yrs | CA$70.00k | 1.33% $ 1.7m | |
| Non-Independent Director | 7.1yrs | CA$30.00k | 0.42% $ 522.8k | |
| Independent Director | 5.7yrs | CA$40.00k | 1.57% $ 2.0m | |
| Independent Director | less than a year | CA$35.00k | no data |
Experienced Board: LOVF.F's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/14 01:13 |
| End of Day Share Price | 2026/01/14 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2025/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cannara Biotech Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Greg McLeish | Research Capital Corporation |